Comparing two ways to lower bad cholesterol in patients after a heart attack

INTERVENTION: Intervention1: Bempedoic Acid and Ezetimibe and Rosuvastatin: Rosuvastatin 20 mg + Ezetimibe 10 mg + Bempedoic acid 180 mg once daily for atleast 12 months Control Intervention1: Rosuvastatin and Ezetimibe: Rosuvastatin 40 mg + Ezetimibe 10 mg once daily, for atleast 12 months CONDITION: Health Condition 1: I248‐ Other forms of acute ischemic heart disease PRIMARY OUTCOME: Percentage change in LDL C from baseline to the Week 4 to 6 visit measured by the central blinded laboratory LDLC is reported by both direct assay and the calculated Martin or Hopkins estimate the direct measurement serves as the primary analytic variableTimepoint: Baseline ; Week 1 ; Week 4 TO 6 ; Week 12 TO 14 every 3 months thereafter to a minimum of 12 months SECONDARY OUTCOME: Key secondary proportion attaining the composite of LDLC less than 55 mg per dL with more than or equal to 50 percentage reduction from baseline at Week 4 to 6 ; Proportion attaining LDL C less than 55 mg per dL at Week 4 to 6 and at each later visit. ; Proportion attaining LDL C more than 40 mg per dL ; Proportion achieving more than or equal to 50 percentage LDL C reduction from baseline ; Absolute change in LDL C and change in non HDLC total cholesterol triglycerides HDLC and apolipoprotein B ; Change in hsCRP from baseline to Week 4 to 6 ; Durability of LDL C goal attainment over followup ; Timepoint: Baseline ; Week 1 ; Week 4 TO 6 ; Week 12 TO 14 every 3 months thereafter to a minimum of 12 INCLUSION CRITERIA: Age greater than or equal to 18 years Diagnosis of acute coronary syndrome ST elevation myocardial infarction non ST elevation myocardial infarction or unstable angina by standard clinical electrocardiographic and biomarker criteria Presentation and ability to be randomized within 24 hours of the inde XACS event Statin naive status Willing and able to provide written informed consent and to attend scheduled follow up